Squarepoint’s ImmunityBio IBRX Stock Holding History

Squarepoint’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$691K	Buy	+73,200	New	+$585K	﹤0.01%	3109

Other funds holding IBRX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Squarepoint's IBRX Position: Q3 2026 in Review

Squarepoint reduced its ImmunityBio (IBRX) stake by 69% in Q3 2026, selling an estimated $4.18M and leaving 237,712 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2099.

Squarepoint first reported a position in IBRX in Q4 2015 and has held it in 19 quarters since. The position peaked at $6.66M in Q2 2026. 274 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

Squarepoint held 237,712 shares of ImmunityBio worth $2.24M as of Q3 2026.
Squarepoint sold 523,281 ImmunityBio shares in Q3 2026, an estimated $4.18M.
ImmunityBio made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #2099 holding.
Squarepoint first reported a position in ImmunityBio in Q4 2015 and has held it in 19 quarters since.
Squarepoint's ImmunityBio position peaked at $6.66M in Q2 2026.
274 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.